Evidence map›Paper›PMID 31442061›Full record

ArticleMolecular pharmaceutics2019

Effect of Dose and Selection of Two Different Ligands on the Deposition and Antitumor Efficacy of Targeted Nanoparticles in Brain Tumors.

Oguz Turan, Peter Bielecki, Kathleen Tong, Gil Covarrubias, Taylor Moon, Abdelrahman Rahmy, Shane Cooley, Youngjun Park, Pubudu M Peiris, Ketan B Ghaghada and 1 more

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Molecular pharmaceutics, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
1.0field-weighted citation impact, top 27% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 7 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Review
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 2 institutions in 1 country.

Oguz TuranDepartment of Biomedical Engineering, School of Medicine , Case Western Reserve University , Cleveland , Ohio 44106 , United States.
Peter BieleckiDepartment of Biomedical Engineering, School of Medicine , Case Western Reserve University , Cleveland , Ohio 44106 , United States.
Kathleen TongDepartment of Biomedical Engineering, School of Medicine , Case Western Reserve University , Cleveland , Ohio 44106 , United States.
Gil CovarrubiasDepartment of Biomedical Engineering, School of Medicine , Case Western Reserve University , Cleveland , Ohio 44106 , United States.
Taylor MoonDepartment of Biomedical Engineering, School of Medicine , Case Western Reserve University , Cleveland , Ohio 44106 , United States.
Abdelrahman RahmyDepartment of Biomedical Engineering, School of Medicine , Case Western Reserve University , Cleveland , Ohio 44106 , United States.
Shane CooleyDepartment of Biomedical Engineering, School of Medicine , Case Western Reserve University , Cleveland , Ohio 44106 , United States.
Youngjun ParkDepartment of Biomedical Engineering, School of Medicine , Case Western Reserve University , Cleveland , Ohio 44106 , United States.
Pubudu M PeirisDepartment of Biomedical Engineering, School of Medicine , Case Western Reserve University , Cleveland , Ohio 44106 , United States.
Ketan B GhaghadaEdward B. Singleton Department of Pediatric Radiology , Texas Children's Hospital , Houston , Texas 77030 , United States.
Efstathios KarathanasisDepartment of Biomedical Engineering, School of Medicine , Case Western Reserve University , Cleveland , Ohio 44106 , United States.ORCID 0000-0001-7484-7552
Case Western Reserve University · USTexas Children's Hospital · US

Funding

Interdisciplinary Biomedical Imaging Training ProgramT32EB007509 · NIBIB · CASE WESTERN RESERVE UNIVERSITY · PI DAVID Lynn WILSON, Xin Yu · 2007 to 2026
$5.6M
Treatment of glioblastoma using targeted nanoparticlesU01CA198892 · NCI · CASE WESTERN RESERVE UNIVERSITY · PI KARATHANASIS, EFSTATHIOS · 2015 to 2019
$3.1M
Cancer Imaging and Therapy Analysis Platform (CITAP)R44CA213601 · NCI · BIOINVISION, INC. · PI GARGESHA, MADHUSUDHANA, WILSON, DAVID LYNN · 2018 to 2019
$1.6M
Detection of micrometastasis using a dual-ligand nanoparticleR01CA177716 · NCI · CASE WESTERN RESERVE UNIVERSITY · PI KARATHANASIS, EFSTATHIOS · 2013 to 2017
$1.6M
NCI NIH HHS R01 CA177716NCI NIH HHS R44 CA213601NCI NIH HHS U01 CA198892NIBIB NIH HHS T32 EB007509
6 · The paper itself

Abstract

Deposition of nanoparticles to tumors often can be enhanced by targeting receptors overexpressed in a tumor. However, a tumor may exhibit a finite number of a biomarker that is accessible and targetable by nanoparticles, limiting the available landing spots. To explore this, we selected two different biomarkers that effectively home nanoparticles in brain tumors. Specifically, we used either an α

Indexed as

AnimalsAntibiotics, AntineoplasticApoptosisBrain NeoplasmsCell ProliferationDose-Response Relationship, DrugDoxorubicinDrug CarriersDrug Delivery SystemsFemaleFibronectinsHumansIntegrin alphaVbeta3LigandsMiceMice, NudeAntibiotics, AntineoplasticDoxorubicinDrug CarriersFibronectinsIntegrin alphaVbeta3LigandsPeptide Fragmentsbrain tumorsfibronectin and integrin targetingmesoporous silica nanoparticlesradiofrequency-triggered drug releasetargeted nanoparticles

Identifiers

PMID31442061
PMCPMC6779508
OpenAlexW2969782136

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.